DOI QR코드

DOI QR Code

Economic Evaluation of Prostate Cancer Screening Test as a National Cancer Screening Program in South Korea

  • Shin, Sangjin (National Evidence-based Healthcare Collaborating Agency) ;
  • Kim, Youn Hee (National Evidence-based Healthcare Collaborating Agency) ;
  • Hwang, Jin Sub (National Evidence-based Healthcare Collaborating Agency) ;
  • Lee, Yoon Jae (National Evidence-based Healthcare Collaborating Agency) ;
  • Lee, Sang Moo (National Evidence-based Healthcare Collaborating Agency) ;
  • Ahn, Jeonghoon (National Evidence-based Healthcare Collaborating Agency)
  • 발행 : 2014.04.30

초록

Background: Prostate cancer is rapidly increasing in Korea and professional societies have requested adding prostate specific antigen (PSA) testing to the National Cancer Screening Program (NCSP), but this started a controversy in Korea and neutral evidence on this issue is required more than ever. The purpose of this study was to provide economic evidence to the decision makers of the NCSP. Materials and Methods: A cost-utility analysis was performed on the adoption of PSA screening program among men aged 50-74-years in Korea from the healthcare system perspective. Several data sources were used for the cost-utility analysis, including general health screening data, the Korea Central Cancer Registry, national insurance claims data, and cause of mortality from the National Statistical Office. To solicit the utility index of prostate cancer, a face-to-face interview for typical men aged 40 to 69 was conducted using a Time-Trade Off method. Results: As a result, the increase of effectiveness was estimated to be very low, when adopting PSA screening, and the incremental cost effectiveness ratio (ICER) was analyzed as about 94 million KRW. Sensitivity analyses were performed on the incidence rate, screening rate, cancer stage distribution, utility index, and treatment costs but the results were consistent with the base analysis. Conclusions: Under Korean circumstances with a relatively low incidence rate of prostate cancer, PSA screening is not cost-effective. Therefore, we conclude that adopting national prostate cancer screening would not be beneficial until further evidence is provided in the future.

참고문헌

  1. Ministry for Health, Welfare, and Family Affairs (2005). The Third Korean National Health and Nutrition Examination Survey (KNHNES III) [Korean]. Seoul, Korea: Ministry for Health, Welfare, and Family Affairs.
  2. Kim Y, Jun JW, Choi KS, et al (2011). Overview of the national cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev, 12, 725-30.
  3. Kobayashi T, Goto R, Fukui T, et al (2007). Impact of improvement in specificity of primary screening test on total cost of prostate cancer mass screening. Int J Urol, 14, 805-10. https://doi.org/10.1111/j.1442-2042.2007.01824.x
  4. Krahn MD, Mahoney JE, Eckman MH, et al (1994). Screening for prostate cancer. A decision analytic view. JAMA, 272, 773-80. https://doi.org/10.1001/jama.1994.03520100035030
  5. Ministry of Employment and Labor (2011). 2010 Survey Report on labor conditions by employment type. Seoul, Korea: Ministry of Employment and Labor.
  6. National Health Insurance Corporation (2010). Survey of medical charges paid by patients with health insurance in 2009 [Korean]. Seoul, Korea: National Health Insurance Corporation.
  7. Perez-Niddam K, Thoral F, Charvet-Protat S (1999). Economic evaluation of a prostate cancer screening program in France: a decision model. Crit Rev Oncol Hematol, 32, 167-73. https://doi.org/10.1016/S1040-8428(99)00033-5
  8. Shteynshlyuger A, Andriole GL (2011). Cost-Effectiveness of prostate specific antigen screening in the United States: extrapolating from the European Study of screening for prostate cancer. J Urol, 185, 828-32. https://doi.org/10.1016/j.juro.2010.10.079
  9. Imamura T, Yasunaga H (2008). Economic evaluation of prostate cancer screening with prostate-specific antigen. Int J Urol, 15, 285-8. https://doi.org/10.1111/j.1442-2042.2008.02013.x
  10. Ahn J, Kim YH, Shin S, et al (2010). Research on Methodologies for Evidence Based Healthcare Decision Making Process in Korea. Seoul, Korea: National Evidence based Healthcare Collaborating Agency (NECA).
  11. Hamashima C, Yoshida K (2000). Cost-effectiveness analysis of prostate cancer screening. Environ Health Prev Med, 5, 111-7. https://doi.org/10.1265/ehpm.2000.111
  12. Holmberg H, Carlsson P, Lofman O, et al (1998). Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden. Health Policy, 45, 133-47. https://doi.org/10.1016/S0168-8510(98)00037-2
  13. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  14. Jung KW, Won YJ, Kong HJ, et al (2013). Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat, 45, 1-14. https://doi.org/10.4143/crt.2013.45.1.1
  15. Jung JW, Won YJ, Kong HK, et al (2013). Survival of Korean cancer patients by stage at diagnosis, 2006-2010: national cancer registry study. Cancer Res Treat, 45, 162-71. https://doi.org/10.4143/crt.2013.45.3.162
  16. Kim Y, Hwang JS, Ahn J, et al (2013). Utilities for prostate cancer by cancer stage and treatment step in Korea. Korean J Health Econ and Policy, 19, 1-20.

피인용 문헌

  1. Gender Differences in Marital Disruption among Patients with Cancer: Results from the Korean National Health and Nutrition Examination Survey (KNHANES) vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6547
  2. Cumulative Probability of Prostate Cancer Detection Using the International Prostate Symptom Score in a Prostate-specific Antigen-based Population Screening Program in Japan vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7079
  3. Changes in Clinical Characteristics of Patients with an Initial Diagnosis of Prostate Cancer in Korea: 10-Year Trends Reported by a Tertiary Center vol.33, pp.6, 2018, https://doi.org/10.3346/jkms.2018.33.e42